Healthcare Innovation Alive & Well in SBIO
It's understandable investors are frustrated with broader measures of small-cap equities. They've been hearing about the possibility of smaller stocks outperforming larger counterparts for a while.
This Tech Sector ETF Could Zig Where Others Zag
With tech earnings arriving, many investors are still likely fearing a downturn for key information technology stocks. The so-called Magnificent Seven stocks delivered significant performance for investors last year.
Healthcare Stocks Could Merit Prescriptions in 2025
It's been a long road of disappointment for healthcare stocks. And biotechnology names have been among the worst offenders.
SBIO ETF: Betting On Medical Breakthroughs
ALPS Medical Breakthroughs ETF is rated Hold due to high fees, low yield, and mixed performance compared to other healthcare ETFs. The SBIO ETF focuses on small and mid-cap biotech companies with drugs in Phase II or III FDA trials, offering targeted exposure to medical breakthroughs. Despite an aging population driving healthcare demand, sector headwinds and government budget pressures make healthcare stocks less attractive for generating Alpha.
Biotech Looms as a Way to Beat the Market
Could now be the time to diversify into important tech subsectors? Rate cuts may already be benefiting tech sectors by easing borrowing costs, with more cuts potentially in the offing.
Steady Rate Cuts Feed Surging Biotech ETF SBIO
Yet another rate cut has come and gone, and even with somewhat steady inflation reads, further cuts may be in the pipeline. Debt-heavy areas like tech stand to benefit, but for those already heavily exposed to big tech names, looking elsewhere may appeal.
How Election Results Could Impact Biotech ETFs
Biotech stocks and ETFs are among the assets that responded positively to last week's presidential election results. As just one example, the ALPS Medical Breakthroughs ETF (SBIO) is up 10% for the week ending November 11.
Biotech ETF SBIO Laps Tech Rivals Over 1 Year
If there were a defining sector for investors this year, it has been tech investing. The ascendance of AI has lifted valuations and investor portfolios, boosting the market as a whole.
Tailwinds Emerging for This Biotech ETF
The effects of the Federal Reserve's recent interest rate cut haven't fully been felt by the economy or financial markets. But the first instance of U.S. monetary easing in over four years may be a boon for capital-intensive biotech companies.
Biotech Stocks Are Perking Up. This ETF Is Responding
In a somewhat quiet fashion, long-lagging biotech stocks and exchange traded funds are perking up. The ALPS Medical Breakthroughs ETF (SBIO) is part of that group.
Biotech ETF SBIO Rides Strong Momentum into Rate Cuts
While many investors are on the lookout for ETF opportunities in rate cuts, one particular strategy is already standing out. The biotech ETF SBIO is riding some positive momentum thanks to some major changes in the space this year.
Positive Biotech M&A Activity in 1H Boosts Case for Biotech ETF SBIO
Following some notable uncertainty in recent years, M&A activity looks to be in recovery. In the first half of this year, biotech M&A activity saw some positive numbers, per a new J.P.
